Mechanics Bancorp Q2 profit rises on HomeStreet merger
Reuters2026/07/29 09:57
Overview
US regional bank's Q2 net income and EPS rose from prior quarter
Company completed HomeStreet merger and sold Fannie Mae DUS business line
Noninterest expense fell due to merger-related headcount reductions
Outlook
Company says merger-related cost savings are expected to continue impacting results
Mechanics Bancorp expects to return to 'business as usual' following merger integration
Result Drivers
NONINTEREST INCOME - Higher noninterest income driven by gain on sale of Fannie Mae DUS business line and mortgage servicing rights valuation adjustment
CREDIT LOSS PROVISION - Reversal of provision for credit losses due to changes in modeled loss rates, elimination of certain economic adjustments, and reduced unfunded commitments
EXPENSE REDUCTION - Lower noninterest expense due to decreased salaries and benefits from merger-related headcount reductions
Company press release: ID:nBw8CWLHka
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 EPS |
|
$0.25 |
|
Q2 Net Income |
|
$57.70 mln |
|
Q2 Net Interest Income |
|
$177.17 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the banks peer group is "buy"
Wall Street's median 12-month price target for Mechanics Bancorp is $17.00, about 7.3% above its July 28 closing price of $15.84
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago
Reuters Recommended Reads
July 27 - Richmond Mutual Bancorporation Q2 net income falls on merger costs
July 27 - NBT Bancorp Q2 net income more than doubles on Evans acquisition
July 28 - Regional bank Renasant Q2 adjusted EPS beats analyst estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ
NASDAQ TRADE HALT CONTINUES <EFTY.O> REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:28 AM